Dr. Lal PathLabs

Expanding Middle Class And Digital Health Will Boost Diagnostics

AnalystHighTarget

Not Invested

Community Contributor

Published

25 Jul 25

AnalystHighTarget's Fair Value

₹4,020.00

23.0% undervalued

10 Sep

₹3,096.80

-11.7%

-1.0%

-11.7%

-1.0%

You can edit this narrative until Jul 25 9:15 PM. Then, changes will post as Updates.

Author's Valuation

₹4.02k23.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

₹4.02k

23.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.77%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.73%

Calculation

₹7.77b

Earnings '28

61.55x

PE Ratio '28

₹477.97b

Market Cap '28

₹477.97b

Market Cap '28

83.76m

No. shares '28

₹5.71k

Share Price '28

₹5.71k Share Price '28

Discounted to 2025 @ 12.73% p.a.

₹3.98k

Fair Value '25